Anti-DR5 [PRO95780 (Drozitumab)]

Absolute Antibody

Anti-DR5 [PRO95780 (Drozitumab)]

7

This antibody binds DR5, triggering DR5 clustering and DISC activation in a range of cancer cells, including colorectal cancer and NSCLC cells (Adams, 2009). Conversely, this antibody showed no effector caspase activation or cell death induction in normal human hepatocytes. In vivo, this antibody has been shown to inhibit tumor xenograft growth in a variety of animal models (Varfolomeev, 2009). This antibody was used in IP, immunoblot, ELISA and IF analysis to precisely characterise its interaction with the DR5 ligand (Adams, 2009).

ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ELISA, Other Application

functional/therapeutic; agonist; IP; immunoblot; ELISA; IF

Research Use Only

Monoclonal

PRO95780 (Drozitumab)

TNFRSF10B

TNF receptor superfamily member 10b

CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9, tumor necrosis factor receptor superfamily member 10B, Fas-like protein, TNF-related apoptosis-inducing ligand receptor 2, apoptosis inducing protein TRICK2A/2B, apoptosis inducing receptor TRAIL-R2, cytotoxic TRAIL receptor-2, death domain containing receptor for TRAIL/Apo-2L, death receptor 5, p53-regulated DNA damage-inducible cell death receptor(killer), tumor necrosis factor receptor superfamily, member 10b, tumor necrosis factor receptor-like protein ZTNFR9

Human

IgG1

Tumor necrosis factor receptor superfamily member 10B

Human

The variable domains of this antibody were derived as scFv from a human antibody phage display library, with biotinylated DR5-Fc used to capture DR5-specific phage. The scFv obtained were subsequently reformatted into full-length antibodies.

-20°C,2°C to 8°C

12352203